STREAM Trial - Statins in Multimorbid Older Adults Without Cardiovascular Disease
- Conditions
- Statin Treatment for Primary Prevention
- Interventions
- Other: Statin discontinuation
- Registration Number
- NCT05178420
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Brief Summary
Statins are among the most widely used drugs. While they were found to be effective for primary and secondary prevention of cardiovascular disease (CVD) in middle-aged subjects, their benefits for primary prevention in older adults (aged ≥70 years) without CVD are uncertain, particularly for those with multimorbidity. The aim of this randomized controlled trial (RCT) is to provide guidance on the benefits and risks of statin deprescribing in multimorbid older adults.
- Detailed Description
Background:
Until now, no RCT examining the benefits of statins in primary prevention has exclusively recruited multimorbid participants aged 70 years and older (70+), and 70+ participants are under-represented in most RCTs, including those examining statin benefits for primary prevention. However, statin side effects and drug interactions are common in populations of multimorbid older adults and might negatively impact quality of life. The proportion of patients developing myalgia on statins has been shown to be as high as 5-20% in observational studies; older age and polypharmacy are known risk factors for developing muscle problems under statins. Furthermore, multimorbid older adults with polypharmacy are more likely to experience side effects with statins (e.g. elevated liver enzymes, diabetes, myopathy, rhabdomyolysis) and drug-drug interactions (e.g. antibiotics, antifungals), with the potential consequences of drug toxicity, reduced physical activity, sarcopenia and falls. In practice, statins are often discontinued in multimorbid older adults without CVD after side effects. The net clinical benefit of statins for primary prevention in multimorbid 70+ older adults remains unclear, and the effect of multimorbidity might shift the evidence towards favoring no statin treatment, but no large RCT examined this issue.
Design:
The study is a multicenter, randomized, non-inferiority trial conducted in multiple centers in Switzerland, France and the Netherlands. Study subjects are randomly assigned in a 1:1 ratio to either discontinue (intervention arm) or continue (control arm) statin therapy. The study is open-label, with blinded outcome adjudication. After inclusion the study participants will be followed with phone calls, first after 3 months and then yearly for a mean of 24 months (min. follow-up period 12 months, max. follow-up period 48 months). Outcomes are assessed at each study follow-up.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1881
- Written informed consent
- ≥70 years of age
- Multimorbid with ≥2 coexistent chronic conditions (defined by ICD-10 codes) with an estimated duration of 6 months or more based on clinical decision, besides dyslipidemia treated by statins
- Intake of a statin for ≥80% of the time during the year before enrollment
-
Cardiovascular secondary prevention setting based on previous large statin trials, defined as:
- History of myocardial infarction type 1 (NSTEMI/STEMI), OR
- History of unstable angina, defined as ACS symptomatic at rest, crescendo or new-onset angina (CCS 2 or 3) without ECG or cardiac biomarker changes (based on available documents), OR
- Stable angina pectoris with a documented ischemia on a stress test or with a significant coronary disease defined as a coronary stenosis >50%, OR
- History of percutaneous coronary intervention (balloon or stent) or coronary artery bypass graft, OR
- History of Stroke (does not apply to clearly cardio-embolic causes for stroke e.g. due to atrial fibrillation), OR
- History of Transient Ischemic Attack, defined as transient neurological deficit without diffusion restriction in MRI, OR
- History of carotid revascularization (stent, bypass, CEA (carotid thrombendartectomy)), OR
- History of peripheral arterial disease requiring revascularization (e.g. PTA (percutaneous transluminal angioplasty), stent, femoral TEA (thrombendartectomy), bypass; Fontaine IV)
-
Aortic disease that required a vascular repair or aortic aneurysm with a maximum diameter >5.5 cm (men) or >5.2 cm (women) based on available documents
-
Diagnosis of familial hypercholesterolemia based on Dutch lipid score ≥6 based on available documents (LDL cholesterol, family history, personal history)
-
Elevated risk of death within 3 months after baseline, defined as:
- Hospitalized patients planned for palliative care within 24h of admission OR
- Hospitalized patients with a Palliative Performance Scale (PPS) level <30% (based on situation at least 1 month before hospitalization), this corresponds to an estimated survival of 43% after 3 months; OR
- Patients with an advanced metastatic cancer prognosis of ≤20% survival rate within 1 year after baseline (based on: https://cancersurvivalrates.com)
-
Participation to a clinical trial with potential impact on the STREAM cardiovascular endpoints (based on clinical judgment)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Statin discontinuation Statin discontinuation Discontinuation of statin therapy - statin therapy will be stopped from the next scheduled intake after study inclusion (intervention arm).
- Primary Outcome Measures
Name Time Method Composite endpoint of all-cause death and major non-fatal CV events (non-fatal myocardial infarction, non-fatal ischemic stroke) 24 months The primary endpoint is a composite endpoint of all-cause death and major non-fatal CV events (non-fatal myocardial infarction, non-fatal ischemic stroke). All-cause death (and not CV death only) is chosen to account for a possible shift from CV to other causes of death. The composite endpoint was selected to assess the net clinical benefit in this population with expected high mortality. The clinical event committee which classifies suspected events for the primary and secondary clinical outcomes is blinded. The primary analysis timeframe is at 24 months, and data collection is performed up to 48 months.
- Secondary Outcome Measures
Name Time Method Non-CV death up to 48 months All deaths except of deaths due to major CV events
Major CV events up to 48 months CV death, non-fatal myocardial infarction and non-fatal ischemic stroke
All-cause death up to 48 months All deaths (for any reason)
Total CV events up to 48 months CV death, non-fatal myocardial infarction, hospitalization for unstable angina, non-fatal ischemic stroke (including TIA) and arterial revascularization (coronary and peripheral urgent and non-urgent revascularization)
Total composite events up to 48 months All-cause death, non-fatal myocardial infarction, hospitalization for unstable angina, non-fatal ischemic stroke (including TIA) and arterial revascularization (coronary and peripheral urgent and non-urgent revascularization)
Verbal numeric pain rating score (VNPRS) 3 months To assess statin associated muscle symptoms. The VNPRS is an 11-point scale scored from 0-10, with higher scores indicating higher degree of pain.
Self-reported falls 12 months Self-reported falls, each participant will collect and list all falls during the first 12 months after randomization. Circumstances and medical consequences of each fall will be collected. Aggregated as rate of falls (falls per person per year).
Composite endpoint of all-cause death and major non-fatal CV events (non-fatal myocardial infarction, non-fatal ischemic stroke) up to 48 months Composite endpoint of all-cause death and major non-fatal CV events (non-fatal myocardial infarction, non-fatal ischemic stroke).
EQ-5D questionnaire 3, 12 (primary analysis), 24, 36, 48 months EQ-5D is the name of the instrument and not an acronym. General quality of life assessment. The possible range of scores goes from 0 to 1.0, with higher scores indicating better quality of life.
Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F questionnaire) 12 (primary analysis), 24, 36, 48 months 5-item questionnaire, the score ranges from 0 to 10 with higher scores indicating higher degree of sarcopenia.
Girerd medication adherence scale 12 (primary analysis), 24, 36, 48 months 6-item questionnaire, the score ranges from 0 to 6, higher scores indicating worse medication adherence.
Trial Locations
- Locations (24)
HFR Fribourg
🇨🇭Fribourg, Switzerland
Hôpital La Tour
🇨🇭Geneva, Switzerland
Hospital Burgdorf
🇨🇭Burgdorf, Switzerland
Stadtspital Triemli
🇨🇭Zuerich, Switzerland
UNIVERSITY HOSPITAL CENTER of Bordeaux
🇫🇷Bordeaux, Nouvelle Acquitaine, France
Leids Universitair Medisch Centrum
🇳🇱Leiden, South Holland, Netherlands
Klinik Barmelweid AG
🇨🇭Barmelweid, Aargau, Switzerland
Centre hospitalier Bienne
🇨🇭Bienne, Bern, Switzerland
Kantonsspital Graubünden
🇨🇭Chur, Graubünden, Switzerland
Luzerner Höhenklinik Montana AG
🇨🇭Crans-Montana, Valais, Switzerland
Spital Limmattal
🇨🇭Schlieren, Zürich, Switzerland
Kantonsspital Aarau
🇨🇭Aarau, Switzerland
Kantonsspital Baden
🇨🇭Baden, Switzerland
Universitätsspital Basel
🇨🇭Basel, Switzerland
Ospedale Regionale di Bellinzona e Valli
🇨🇭Bellinzona, Switzerland
Clinic for General Internal Medicine, Bern University Hospital Bern
🇨🇭Bern, Switzerland
Hôpitaux Universitaires de Genève (Geriatrics)
🇨🇭Geneva, Switzerland
Hôpitaux Universitaires de Genève (Internal Medicine)
🇨🇭Geneva, Switzerland
Hospital Langnau
🇨🇭Langnau im Emmental, Switzerland
CHUV Lausanne
🇨🇭Lausanne, Switzerland
Hôpital Neuchâtelois
🇨🇭Neuchâtel, Switzerland
Hospital St. Gallen (Geriatrics)
🇨🇭Saint Gallen, Switzerland
Kantonsspital Schaffhausen
🇨🇭Schaffhausen, Switzerland
Stadspital Waid
🇨🇭Zuerich, Switzerland